The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.



Latest Headlines

Latest Headlines

Early Gilenya generics now spell trouble for rival MS drugs

Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.

Novartis targets Amgen's Enbrel with second biosimilar app

Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.

Novartis comes for Enbrel in latest biosimilar shot at Amgen

A month removed from launching the U.S.'s first biosimilar, Novartis is again setting sights on an Amgen cash cow, lining up for FDA approval with a copy of the blockbuster Enbrel.

Facing a crisis, Xoma buys time with a $517M Novartis deal

Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.

Novartis stacks up more data for lucrative Cosentyx expansion

Novartis is chasing a pair of new uses for brand-new psoriasis med Cosentyx, and when it comes to psoriatic arthritis, it's piling up the positive data.

UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster Gilenya, handing a win to challenger Torrent Pharmaceuticals--and fellow generics makers Mylan and Apotex, which had filed a separate challenge.

Novartis issues voluntary recall of ADHD drug manufactured in Georgia

Novartis has issued a voluntary recall of more than 10,000 bottles of a drug used to treat attention deficit hyperactivity disorder (ADHD) that were manufactured at a plant in Georgia.

Novartis backs DC Comics graphic novel starring rare-disease hero and his canine sidekick

Batman and Superman can add another superhero to their ranks at publisher DC Comics, and that's Scott. The teenage protagonist and his trusty sidekick--Turbo the toy dog--feature in the company's latest graphic novel, which Novartis partnered to create for teens with tuberous sclerosis complex.

Novartis scores EU rec for blockbuster-to-be Entresto

Novartis has predicted that its launch of newly FDA-approved heart failure med Entresto would be its "most exciting" ever. And now, it's one step closer to bringing that excitement to Europe.

Novartis' top scientist is stepping down after 13 years, making way for a Harvard luminary

Mark Fishman, head of Novartis' $10 billion research operation, is retiring next year, making way for an award-winning Harvard oncologist after 13 years at the helm.